William Blair analyst Sami Corwin has maintained their bullish stance on SLDB stock, giving a Buy rating today.
Sami Corwin has given his Buy rating due to a combination of factors that highlight Solid Biosciences’ promising advancements in gene therapy. The company has successfully completed IND-enabling studies for its SGT-501 program, targeting a rare cardiac condition, and is on track to submit an IND by mid-2025. This progress, along with plans to engage with the FDA for accelerated approval, underscores the potential for significant clinical milestones.
Additionally, Solid Biosciences’ initial clinical update for SGT-003 has shown promising results, validating the safety and efficacy of their AAV-SLB101 capsid. The consistent expression of microdystrophin in patients suggests a strong potential for long-term benefits. These developments, along with the company’s strategic pipeline expansion in cardiac and neuromuscular therapies, contribute to the positive outlook and justify the Buy rating.
In another report released today, Barclays also maintained a Buy rating on the stock with a $15.00 price target.